Presbia PLC (NASDAQ:LENS) Receiving Positive Media Coverage, Study Shows

Media coverage about Presbia PLC (NASDAQ:LENS) has been trending positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Presbia PLC earned a coverage optimism score of 0.29 on Accern’s scale. Accern also assigned media stories about the medical instruments supplier an impact score of 45.6392858188911 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Receive News & Ratings for Presbia PLC Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Presbia PLC (LENS) traded up 1.11% during mid-day trading on Friday, reaching $2.46. 16,165 shares of the company were exchanged. Presbia PLC has a 1-year low of $1.86 and a 1-year high of $5.07. The stock has a 50-day moving average of $2.34 and a 200 day moving average of $2.81. The firm’s market capitalization is $41.71 million.

LENS has been the topic of a number of research reports. Rodman & Renshaw cut their target price on shares of Presbia PLC from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday, May 22nd. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Presbia PLC in a report on Tuesday, May 23rd. Finally, Zacks Investment Research cut shares of Presbia PLC from a “hold” rating to a “sell” rating in a report on Wednesday, May 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $12.00.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by [[site]] and is the sole property of of [[site]]. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at [[permalink]].

About Presbia PLC

Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.